Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NOVO NORDISK INC.
Novo’s investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology
November 14, 2026
Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval
November 13, 2026
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician’s real-life “Walk, Golf, and Wegovy®” diet and weight-loss routine
November 12, 2026
Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026
November 8, 2026
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
November 6, 2026
New research initiative will utilise AI to optimise Nordic energy grid capacity, improve resilience and prepare for future needs
November 3, 2026
Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world
October 29, 2026
Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at The Liver Meeting® (AASLD) 2026
October 28, 2026
Novo’s Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes
October 23, 2026
Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting
October 21, 2026
1
2
3
Next Page
→